热门资讯> 正文
INDVIO宣布2500万美元公开募股定价
2025-07-03 19:57
- 伊诺维奥制药(INO) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- INOVIO Pharmaceuticals (NASDAQ:INO) on Thursday priced an underwritten public offering of 14.29 million shares of its common stock, along with accompanying Series A and Series B warrants to purchase up to an additional 28.57 million shares. Each share of common stock is being sold together with one Series A warrant and one Series B warrant at a combined public offering price of $1.75. Both warrants carry an exercise price of $1.75 per share. In lieu of shares, investors may also opt to receive pre-funded warrants.
- The offering is expected to close on or about July 7, 2025, subject to the satisfaction of customary closing conditions.
- The gross proceeds from the offering are expected to be around $25 million.
- INO -23.36% premarket to $1.64.
- Source: Press Release
More on Inovio Pharmaceuticals
- Inovio Pharmaceuticals announces proposed public offering of common stock and warrants
- Crispr Therapeutics, Clover Health among healthcare stocks to join Russell 3000; INO, SAVA to exit
- Seeking Alpha’s Quant Rating on Inovio Pharmaceuticals
推荐文章
美股机会日报 | 特朗普放大招！9万亿养老金即将杀入加密市场；美联储主席候选人支持7月降息
一周财经日历 | 特斯拉、谷歌财报重磅来袭！维立志博将于下周五登陆港交所
一图看懂 | 港股上半年IPO募资额登顶全球！中签就赚一万港币的“大肉签”你参与了吗？
华盛早报丨重大突破！三大加密货币法案众议院闯关成功；美联储，降息大消息
黄仁勋年内三度访华！H20重返中国市场，释放了什么信号？
创新药行情彻底爆发！维立志博-B打新半日孖展超购130倍，冻资近150亿港元
新股申购 | 维立志博-B入场费3535.30港元！引入腾讯、易方达等基石投资者
7月财报预告丨迎关税考验！特斯拉、台积电放榜在即，美股能否守住涨势？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
